Silo Pharma, Inc.
SILOOther · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | — | $40,923 |
| Operating income | −$4.3M | −$4.7M | −$3.9M | −$3.6M | −$2.7M | −$2.2M |
| Net income | −$4.2M | −$4.4M | −$3.7M | −$3.9M | $3.9M | −$3.0M |
| Total assets | $7.6M | $7.4M | $7.7M | $11.6M | $10.5M | $1.4M |
| Total liabilities | $1.3M | $2.4M | $1.6M | $1.3M | $1.4M | $145,969 |
| Equity | $6.3M | $5.0M | $6.2M | $10.3M | $9.1M | $1.3M |
| EPS (diluted) | $-0.50 | $-1.19 | $-1.20 | — | $0.04 | $-0.05 |
| Shares out. | 4.5M | 2.8M | 3.2M | 98.7M | 85.2M | 23.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −5937.0%
- Net margin
- −5863.5%
- Return on equity
- −67.0%
- Return on assets
- −55.6%
- Return on capital (ROCE)
- −61.5%
- Liabilities / assets
- 17.1%
- Debt / equity
- 0.21×
- Book value / share
- $1.41
- Revenue growth (YoY)
- 0.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.23distress
- Accruals / assets
- 5.7%moderate
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2019
- NT 10-Qmissed a reporting deadline ↗May 15, 2017
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2016
- NT 10-Qmissed a reporting deadline ↗May 17, 2016
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2016
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2015
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Anson Funds Management LpPassive (13G)Feb 17, 2026
- Intracoastal Capital, LlcPassive (13G)Feb 13, 2026
- Seg Opportunity Fund, LlcPassive (13G)Feb 13, 2026
- Renaissance Technologies LlcPassive (13G)Feb 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Weisblum EricOfficer — Chief Executive Officer | Dec 15, 2025 | Buy | 2,500 | $0.41 |
| Weisblum EricOfficer — Chief Executive Officer | Nov 20, 2025 | Buy | 1,000 | $0.37 |
| Weisblum EricOfficer — Chief Executive Officer | Nov 18, 2025 | Buy | 7,500 | $0.40 |
| Weisblum EricOfficer — Chief Executive Officer | May 27, 2025 | Buy | 10,000 | $0.43 |
| Weisblum EricOfficer — CEO and President | Dec 13, 2024 | Buy | 2,500 | $0.84 |
| Weisblum EricOfficer — CEO and President | Nov 20, 2024 | Buy | 2,500 | $0.95 |
| Weisblum EricOfficer — CEO and President | Jun 11, 2024 | Buy | 562 | $1.08 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 728,373 | 2.5 | -5.7% |
| Apr 30, 2026 | 772,585 | 1.0 | +47.9% |
| Apr 15, 2026 | 522,541 | 1.0 | +58.6% |
| Mar 31, 2026 | 329,449 | 1.6 | +3.0% |
| Mar 13, 2026 | 319,975 | 1.4 | -45.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Entered a material agreement · Unregistered equity saleApr 2, 2026
- Unregistered equity sale · Other material eventFeb 23, 2026
- Delisting / listing-standard noticeDec 29, 2025
- Director / officer change · Shareholder voteOct 24, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventOct 1, 2025
- Other material eventAug 5, 2025
- Entered a material agreement · Unregistered equity sale · Other material eventJul 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTJun 1, 2026
- 10-QQUARTERLY REPORTMay 14, 2026
- 424B3PROSPECTUSApr 16, 2026
- EFFECTApr 15, 2026
- 424B3PROSPECTUSApr 14, 2026
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1Apr 14, 2026
- EFFECTApr 13, 2026
- POS AMPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1Apr 10, 2026
- 8-KCURRENT REPORTApr 2, 2026
- 10-KANNUAL REPORTMar 27, 2026
- 8-KCURRENT REPORTFeb 23, 2026
- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 13, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 8-KCURRENT REPORTDec 29, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.